@DucreuxMichel https://t.co/7TLiBUJbUp . @KoheiShitara REVERCE2 ongoing to confirm findings in US patients. 3. Similar studies have shown similar OS results . BACCI (https://t.co/5tzsKitLnn) @GIcancerDoc . 4. Why was SOLSTICE negative? TAS102/bev vs cape?
@DucreuxMichel After having time to think about the results, don’t believe the hype. The discussant failed to mention 3 key points. 1. Is this a bev naive effect (~30% had no prior bev exposure). 2 is this a sequencing effect? Rego has shown better OS when given in third line therapy (1/3)
NAPOLI-3 positive. Historical retrospective data suggests no difference in survival between FOLFIRINOX and gem abraxane. Maybe naliri isn’t the same as iri? Looking forward to see data. @GIcancerDoc https://t.co/0gRBzXpCOI
@R_Brauninger That’s the take home? Should be: 1. O line is terrible, Aki needs to take a seat permanently on the bench. 2. Jimbo needs an OC and 3. Jimbo needs an OC. Play call, time management (wasted two timeouts in the second half).
Next up at @KRASKickers Connect Patient conference today.
Targeting KRAS: From the
“Undruggable” to Druggable in Colorectal Cancer
Daniel Ahn, D.O. , M.S. , Mayo Clinic
@the_danielahn@MayoClinic
@MarkYarchoan@graokane Sounds like from the press release, PFS was also missed which cannot be attributed to second line ICIs. It will be interesting to see the data.
It is time we started treating radiation as experimental therapy in pancreatic cancer and found a way to prove its utility. I still use it where I believe it helps--such things as clearing margins and getting people time off systemic therapy, but would be nice to prove benefit